Primary Testicular and Cutaneous Philadelphia Chromosome Positive B-Cell Lymphoblastic Lymphoma: A Rare Case and Review

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi:10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Ferreri A, Hoelzer D, et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2017;113:304–317. doi:10.1016/j.critrevonc.2017.03.020
   PubMed Web of Science ®Google Scholar
• Lin P, Jones D, Dorfman DM, et al. Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol. 2000;24(11):1480–1490. doi:10.1097/00000478-200011000-00003
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(9):1079–1109. doi:10.6004/jnccn.2021.0042
   PubMedGoogle Scholar
• Yasuda T, Tsuzuki S, Kawazu M, et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016;48(5):569–574. doi:10.1038/ng.3535
   PubMed Web of Science ®Google Scholar
• Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7(1):11790. doi:10.1038/ncomms11790
   PubMedGoogle Scholar
• Clappier E, Auclerc MF, Rapion J, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28(1):70–77. doi:10.1038/leu.2013.277
   PubMed Web of Science ®Google Scholar
• Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39. doi:10.1186/s13045-019-0729-2
   PubMed Web of Science ®Google Scholar
• Sadrzadeh H, Huck AE, Chen YB, et al. Philadelphia chromosome positive B-cell lymphoblastic lymphoma isolated to bone. Leuk Lymphoma. 2013;54(9):2052–2054. doi:10.3109/10428194.2012.760735
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang S, Zhu L, et al. Primary testicular Ph-positive B lymphoblastic lymphoma: an unusual presentation and review. Cancer Biol Ther. 2015;16(8):1122–1127. doi:10.1080/15384047.2015.1056412
   PubMed Web of Science ®Google Scholar
• Boddu P, Yin CC, Kanagal-Shamanna R, et al. An unsuspected finding of t (9;22): a rare case of Philadelphia chromosome-positive B-lymphoblastic lymphoma. Case Rep Hematol. 2017;2017:2413587. doi:10.1155/2017/2413587
   PubMedGoogle Scholar
• Alshomar A, El Fakih R. Philadelphia chromosome-positive lymphoblastic lymphoma-Is it rare or underdiagnosed? Hematol Oncol Stem Cell Ther. 2020;13(4):242–243. doi:10.1016/j.hemonc.2018.05.007
   PubMedGoogle Scholar
• Dragani M, Andreani G, Fava C, et al. Philadelphia-positive lymphoblastic lymphoma: a case report and review of the literature. Stem Cell Investig. 2019;6:17. doi:10.21037/sci.2019.06.06
   PubMedGoogle Scholar
• Takahashi T, Ichikawa S, Ichinohasama R, et al. BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with t (9;22); BCR-ABL1? Leuk Lymphoma. 2020;61(5):1265–1267. doi:10.1080/10428194.2019.1706736
   PubMed Web of Science ®Google Scholar
• Yamada C, Shimomura Y, Kamijyo K, et al. BCR/ABL1-positive B-lymphoblastic lymphoma successfully treated with dasatinib-combined chemotherapy. Intern Med. 2021;60(19):3149–3153. doi:10.2169/internalmedicine.7066-21
   PubMed Web of Science ®Google Scholar
• Li X, Cao W, Zhang S, et al. Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: a rare case report and literature review. Medicine. 2021;100(23):e26323. doi:10.1097/MD.0000000000026323
   PubMed Web of Science ®Google Scholar
• Heerema NA, Sather HN, Ge J, et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t (4;11) - a report of the Children’s Cancer Group. Leukemia. 1999;13(5):679–686. doi:10.1038/sj.leu.2401413
   PubMed Web of Science ®Google Scholar
• Mater DV, Goodman BK, Wang E, et al. MLL duplication in a pediatric patient with B-cell lymphoblastic lymphoma. J Pediatr Hematol Oncol. 2012;34(3):e120–e123. doi:10.1097/MPH.0b013e3182273b57
   PubMed Web of Science ®Google Scholar
• Shen S, Chen X, Cai J, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):358–366. doi:10.1001/jamaoncol.2019.5868
   PubMed Web of Science ®Google Scholar
• Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019;134(16):1351–1355. doi:10.1182/blood.2019001244
   PubMed Web of Science ®Google Scholar
• Møller MB, d’Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. Eur J Cancer. 1994;30(12):1760–1764. doi:10.1016/0959-8049(94)00311-r
   Web of Science ®Google Scholar
• Abdelhalim A, Barcos M, Block AW, et al. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leuk Lymphoma. 2007;48(5):1053–1056. doi:10.1080/10428190701258370
   PubMed Web of Science ®Google Scholar
• Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112(4):1005–1012. doi:10.1182/blood-2008-02-140665
   PubMed Web of Science ®Google Scholar
• Foà R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for Ph-Positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–1623. doi:10.1056/NEJMoa2016272
   PubMed Web of Science ®Google Scholar